A BAYESIAN NETWORK META-ANALYSIS (NMA) OF IBRUTINIB VS BENDAMUSTINE-RITUXIMAB FOR TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKAEMIA (TN-CLL) PATIENTS WITH CIRS R 6 OR CLCR Z 60 ML/MIN

OBJECTIVES: Ibrutinib has demonstrated superiority in terms of efficacy and toler-ability to chlorambucil (Chi) for TN-CLL patients who are elderly or unfit (RESONATE-2). Within this trial there is a subgroup of less fragile patients, defined as those having a Cumulative Illness Rating Scale (QRS) s...

Ausführliche Beschreibung